Efficacy of an inactivated bivalent vaccine against the prevalent strains of Newcastle disease and H9N2 avian influenza

Table 3 Immune protection against H9 AIV isolated in 2012–2014

Virus for challenge	Group	HI titer (log2)	Clinical signs/total	Deaths/total	Positive swabs/total	Protection rate (%)^a
H9-JS12	G	9.2	0/10	0/10	0/10^c	100
H9-JS12	J	0.0	1/5	1/5	5/5	0
H9-HB13	H	9.3	0/10	0/10	0/10	100
H9-HB13	K	0.0	1/5	1/5	5/5	0
H9-SD14	I	8.7	0/10	0/10	0/10	100
H9-SD14	L	0.0	0/5	0/5	5/5	0
-	M	0.0	0/5	0/5	0/5^b,c	100

^aProtection definition: means survival without signs of clinical disease not shedding
^bCloaca swab
^cThroat swab

ISSN: 1743-422X